CRP and the disposal of dying cells: Consequences for systemic lupus erythematosus and rheumatoid arthritis

References

• Thompson S, Kelly CA, Griffiths ID, Turner GA. Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease. Clin Chim Acta 1989; 184(3)251–258
   PubMed Web of Science ®Google Scholar
• Walsh L, Davies P, McConkey B. Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis. Ann Rheum Dis 1979; 38(4)362–363
   PubMedGoogle Scholar
• Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1982; 9(2)224–228
   PubMed Web of Science ®Google Scholar
• Walters MT, Stevenson FK, Goswami R, Smith JL, Cawley MI. Comparison of serum and synovial fluid concentrations of beta 2-microglobulin and C reactive protein in relation to clinical disease activity and synovial inflammation in rheumatoid arthritis. Ann Rheum Dis 1989; 48(11)905–911
   PubMed Web of Science ®Google Scholar
• Mallya RK, Vergani D, Tee DE, Bevis L, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol 1982; 48(3)747–753
   PubMedGoogle Scholar
• Swaak AJ, van Rooyen A, Nieuwenhuis E, Aarden LA. Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol 1988; 17(6)469–474
   PubMed Web of Science ®Google Scholar
• Rowe IF, Sheldon J, Riches PG, Keat AC. Comparative studies of serum and synovial fluid C reactive protein concentrations. Ann Rheum Dis 1987; 46(10)721–726
   PubMedGoogle Scholar
• Bell SA, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998; 113(3)327–332
   PubMedGoogle Scholar
• Du Clos TW, Zlock LT, Hicks PS, Mold C. Decreased autoantibody levels and enhanced survival of (NZB × NZW) F1 mice treated with C-reactive protein. Clin Immunol Immunopathol 1994; 70(1)22–27
   PubMedGoogle Scholar
• Ogden CA, Elkon KB. Single-dose therapy for lupus nephritis: C-reactive protein, nature's own dual scavenger and immunosuppressant. Arthritis Rheum 2005; 52(2)378–381
   PubMedGoogle Scholar
• Rodriguez W, Mold C, Marnell LL, Hutt J, Silverman GJ, Tran D, Du Clos TW. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006; 54(1)325–335
   PubMedGoogle Scholar
• Szalai AJ, Weaver CT, McCrory MA, van Ginkel FW, Reiman RM, Kearney JF, Marion TN, Volanakis JE. Delayed lupus onset in (NZB × NZW) F1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003; 48(6)1602–1611
   PubMedGoogle Scholar
• Sheriff A, Gaipl US, Voll RE, Kalden JR, Herrmann M. Apoptosis and systemic lupus erythematosus. Rheum Dis Clin North Am 2004; 30(3)505–527, viii–ix
   PubMedGoogle Scholar
• Sjowall C, Eriksson P, Almer S, Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002; 19(3)155–160
   PubMed Web of Science ®Google Scholar
• Sjowall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004; 6(2)R87–R94
   Google Scholar
• Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13(1)137–147
   PubMed Web of Science ®Google Scholar
• Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H. A role for secretory phospholipase A2 and C-reactive protein in the removal of injured cells. Immunol Today 1997; 18(3)111–115
   PubMedGoogle Scholar
• Nijmeijer R, Willemsen M, Meijer CJ, Visser CA, Verheijen RH, Gottlieb RA, Hack CE, Niessen HW. Type II secretory phospholipase A2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003; 285(5)H2218–H2224
   Google Scholar
• Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112(6)2135–2147
   PubMedGoogle Scholar
• Siegel J, Osmand AP, Wilson MF, Gewurz H. Interactions of C-reactive protein with the complement system II. C-reactive protein-mediated consumption of complement by poly-l-lysine polymers and other polycations. J Exp Med 1975; 142(3)709–721
   PubMedGoogle Scholar
• Volanakis JE, Narkates AJ. Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway. Mol Immunol 1983; 20(11)1201–1207
   PubMedGoogle Scholar
• Volanakis JE. Complement-induced solubilization of C-reactive protein-pneumococcal C-polysaccharide precipitates: evidence for covalent binding of complement proteins to C-reactive protein and to pneumococcal C-polysaccharide. J Immunol 1982; 128(6)2745–2750
   PubMedGoogle Scholar
• Volanakis JE. Human C-reactive protein: Expression, structure, and function. Mol Immunol 2001; 38(2–3)189–197
   PubMed Web of Science ®Google Scholar
• Scott DL. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39(Suppl 1)24–29
   PubMedGoogle Scholar
• Feldmann M, Elliott MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283–350
   PubMed Web of Science ®Google Scholar
• Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, Emery P. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005; 52(1)42–48
   PubMedGoogle Scholar
• Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993; 90(24)11924–11928
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133(10)795–799
   PubMedGoogle Scholar
• Loftus EV, Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ, 3rd. Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County. Gastroenterology, Minnesota 2002; 123: 468–475, 2
   Google Scholar
• Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306(6877)558
   PubMed Web of Science ®Google Scholar
• Schett G, Kiechl S, Weger S, Mayr A, Oberhollenzer F, Lorenzini R, Redlich K, Zwerina J, Willeit J. High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck Study. Arch Intern Med 2006; 22: 2495–2501
   Google Scholar
• Cai H, Song C, Lim IG, Krilis SA, Geczy CL, McNeil HP. Importance of C-reactive protein in regulating monocyte tissue factor expression in patients with inflammatory rheumatic diseases. J Rheumatol 2005; 32(7)1224–1231
   PubMedGoogle Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, Garcia-Porrua C, Testa A, Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005; 32(7)1219–1223
   PubMedGoogle Scholar
• Forsblad D'Elia H, Larsen A, Waltbrand E, Kvist G, Mellstrom D, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62(7)617–623
   PubMedGoogle Scholar
• Pepys MB, Lanham JG, De Beer FC. C-reactive protein in SLE. Clin Rheum Dis 1982; 8(1)91–103
   PubMedGoogle Scholar
• Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91(4)1351–1357
   PubMed Web of Science ®Google Scholar
• Rosenau BJ, Schur PH. Antibodies to C reactive protein. Ann Rheum Dis 2006; 65(5)674–676
   PubMedGoogle Scholar
• Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41(7)1241–1250
   PubMed Web of Science ®Google Scholar
• Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46(1)191–201
   PubMed Web of Science ®Google Scholar
• Botto M, Dell'Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19(1)56–59
   PubMed Web of Science ®Google Scholar
• Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998; 7(2)113–118
   PubMed Web of Science ®Google Scholar
• Herrmann M, Zoller OM, Hagenhofer M, Voll R, Kalden JR. What triggers anti-dsDNA antibodies?. Mol Biol Rep 1996; 23(3–4)265–267
   PubMedGoogle Scholar
• Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, Matsushima GK. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001; 411(6834)207–211
   PubMed Web of Science ®Google Scholar
• Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192(3)359–366
   PubMed Web of Science ®Google Scholar
• Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000; 25(2)177–181
   PubMed Web of Science ®Google Scholar
• Bickerstaff MC, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, Mitchell DA, Cook HT, Butler PJ, Walport MJ. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5(6)694–697
   PubMed Web of Science ®Google Scholar
• Chitrabamrung S, Rubin RL, Tan EM. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol Int 1981; 1(2)55–60
   PubMed Web of Science ®Google Scholar
• Agnello V, De Bracco MM, Kunkel HG. Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol 1972; 108(3)837–840
   PubMedGoogle Scholar
• Hauptmann G, Grosshans E, Heid E, Mayer S, Basset A. Acute lupus erythematosus with total absence of the C4 fraction of complement. Nouv Presse Med 1974; 3(14)881–882
   PubMedGoogle Scholar
• Hartung K, Baur MP, Coldewey R, Fricke M, Kalden JR, Lakomek HJ, Peter HH, Schendel D, Schneider PM, Seuchter SA. Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 1992; 90(4)1346–1351
   PubMedGoogle Scholar
• Petry F. Molecular basis of hereditary C1q deficiency. Immunobiology 1998; 199(2)286–294
   PubMedGoogle Scholar
• Morgan BP, Walport MJ. Complement deficiency and disease. Immunol Today 1991; 12(9)301–306
   PubMedGoogle Scholar
• Moroni G, Trendelenburg M, Del Papa N, Quaglini S, Raschi E, Panzeri P, Testoni C, Tincani A, Banfi G, Balestrieri G. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37(3)490–498
   PubMed Web of Science ®Google Scholar